Drug Approval | February 24, 2024
Orchid Pharma's 'Exblifep' receives USFDA approval
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
_256_384.jpg)
The Vice President also highlighted the importance of preventive healthcare and fitness
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Global Initiative on Digital Health (GIDH) was launched by the WHO and the Government of India during the G20 Health Working Group meeting in Gandhinagar last year
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
The launch of a DGCA Type Approved Logistics Drone facilitates critical medical deliveries to remote regions
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Subscribe To Our Newsletter & Stay Updated
